ArticleMedicine2026
Gastric cancer burden from 1990 to 2021, Joinpoint analysis, projections to 2036, and health inequality assessment: Findings from the Global Burden of Disease study 2021.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastric cancer (GC) remains a major global health issue with high incidence and mortality. This study evaluates the global burden and health disparities of GC from 1990 to 2021 and projects trends through 2036, providing evidence for targeted control measures. The data were sourced from the 2021 Global Burden of Disease study, covering the incidence, mortality, disability-adjusted life years, age-standardized incidence rate, age-standardized mortality rate, and age-standardized disability-adjusted life years rate of GC across 204 countries and regions from 1990 to 2021. Joinpoint regression analysis was employed to examine trends between 1990 and 2021, while a Bayesian age-period-cohort model was constructed to assess and project trends up to 2036. Concentration curves and concentration indices were used to examine cross-national relative inequalities in GC burden across sociodemographic index (SDI) levels. Compared to 1990, the number of GC cases and deaths increased in 2021; meanwhile, the age-standardized incidence rate, age-standardized mortality rate, and age-standardized disability-adjusted life years rate declined, respectively. Males consistently faced a higher disease burden across all age groups. The gap between high-SDI and low-SDI countries is narrowing, with underdeveloped countries bearing a relatively heavier burden of stomach cancer. The Bayesian age-period-cohort model predicts a further decline in the global GC burden by 2036. GC remains a substantial global burden, affecting regions and countries worldwide with pronounced geographic, age, and sex-related disparities. Effective interventions - such as Helicobacter pylori prevention and treatment, as well as widespread early GC screening - are crucial for reducing incidence risks and improving survival outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.